Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats.

about

Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats.

Item

http://www.wikidata.org/entity/Q52145020

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Liquid Chromatography-Mass Spe ...... atinib in Sprague-Dawley Rats.

@en

Liquid Chromatography-Mass Spe ...... atinib in Sprague-Dawley Rats.

@nl

type

Item

label

Liquid Chromatography-Mass Spe ...... atinib in Sprague-Dawley Rats.

@en

Liquid Chromatography-Mass Spe ...... atinib in Sprague-Dawley Rats.

@nl

prefLabel

Liquid Chromatography-Mass Spe ...... atinib in Sprague-Dawley Rats.

@en

Liquid Chromatography-Mass Spe ...... atinib in Sprague-Dawley Rats.

@nl

P1476

Liquid Chromatography-Mass Spe ...... atinib in Sprague-Dawley Rats.

@en

P2093

Fei Fei

http://www.w3.org/2001/XMLSchema#string

Guangji Wang

http://www.w3.org/2001/XMLSchema#string

Hongbo Wang

http://www.w3.org/2001/XMLSchema#string

Jingqiu Huang

http://www.w3.org/2001/XMLSchema#string

Jiye Aa

http://www.w3.org/2001/XMLSchema#string

Pei Wang

http://www.w3.org/2001/XMLSchema#string

Shuyao Wang

http://www.w3.org/2001/XMLSchema#string

Siqi Feng

http://www.w3.org/2001/XMLSchema#string

Xiaolan Zhang

http://www.w3.org/2001/XMLSchema#string

Ying Peng

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor α1

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase includ

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Effects of food on the pharmacokinetics of ponatinib in healthy subjects.

Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice.

The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2

P2888

s40487-016-0022-2

P304

117-128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40487-016-0022-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28261644

http://www.w3.org/2001/XMLSchema#string

P932

5315062

http://www.w3.org/2001/XMLSchema#string